## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -6.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($87.99)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Boston Scientifc pays $188 million for newly built Maple Grove facility**
- Source: The Business Journals | 20251208T130806 | Bullish | Relevance: 99%
- Boston Scientific has paid $188 million for a newly constructed, 400,000-square-foot facility in Maple Grove, expanding its significant presence in the northwest metro. The company's continued growth in the area is highlighted by this substantial real estate acquisition.

**2. Boston Scientific buys major Minneapolis-area property for $188M**
- Source: NBC Boston | 20251209T120809 | Somewhat-Bullish | Relevance: 99%
-  Boston Scientific Corp. has acquired its newly opened 400,000-square-foot facility in Maple Grove, a suburb of Minneapolis, for $188.8 million. This acquisition represents one of the largest commercial real estate transactions of the year. The Maple Grove City Council had previously approved plans for the facility.

**3. Boston Scientific Corporation $BSX Shares Purchased by State Street Corp**
- Source: MarketBeat | 20251209T131410 | Somewhat-Bullish | Relevance: 98%
-  State Street Corp increased its stake in Boston Scientific Corporation (NYSE:BSX) by 1.1% in Q2, acquiring 713,379 additional shares, bringing its total to over 65 million shares valued at approximately $7 billion. Despite institutional buying, company insiders have recently sold over 143,000 shares worth $14.23 million. Boston Scientific reported strong Q3 earnings, beating analyst estimates, and maintains a consensus "Buy" rating with an average target price of $123.77.

**4. Wall Street Analysts Have Consensus Hold Recommendation For Baxter International Inc. (BAX)**
- Source: Finviz | 20251209T055300 | Neutral | Relevance: 63%
- Wall Street analysts have a consensus "Hold" rating for Baxter International Inc. (BAX), with a one-year average share price target of $23.80, representing a 28% upside potential. This comes after Morgan Stanley cut its price target to $15 with an "Underweight" rating, and Argus Research downgraded the stock due to a significant dividend reduction planned for January 2026, aimed at strengthening the balance sheet. Despite favorable trends in medical technology, BAX has seen a 36% year-to-date slump.

**5. Wound Care Market is expected to reach US$ 25.4 billion by 2031 | Major Companies - Smith & Nephew PLC. , Molnlycke Health Care Ab, Baxter International Inc.**
- Source: openPR.com | 20251209T130924 | Somewhat-Bullish | Relevance: 61%
-  The global Wound Care Market, valued at US$ 18.5 billion in 2023, is projected to reach US$ 25.4 billion by 2031, growing at a CAGR of 4.5%. This growth is driven by increasing chronic diseases, surgical procedures, aging populations, and technological advancements in wound management. Key players include Smith & Nephew PLC., Molnlycke Health Care Ab, and Baxter International Inc., among others, with significant recent developments in product launches, clinical trials, and manufacturing expansions across North America and Europe.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $132 | $132 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.0% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 8.7% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.92 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $137.2B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.92 |
| Forward P/E | 26.7 |
| Current P/E | 30.5 |
| YoY Growth | 14.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -2.7% to -6.7% (-4.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.7pp (needs >3.0% for momentum thesis). Below SMA200 (0.91x), long-term trend not supportive. MACD histogram bearish (-0.76), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -6.72% (CS: 3) | Weak |
| RSI_14 | 30.9 | Neutral |
| MACD Histogram | -0.76 | Bearish |
| vs SMA20 | 0.931x | Below |
| vs SMA50 | 0.934x | Below |
| vs SMA200 | 0.913x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $92.53
- **Stop Loss:** $87.99 (4.9% risk)
- **Target:** $97.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 66
- **Position Value:** $6,106.98
- **Portfolio %:** 6.11%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*